Managing the Interplay of Familial Hypercholesterolemia and COVID-19
About 90% of those with familial hypercholesterolemia have not been diagnosed or treated for it, leaving them more vulnerable for COVID-19 infection and its complications.
Dyslipidemia
Rosuvastatin Reduces Inflammatory Markers in People With HIV and Metabolic Syndrome
Study authors assessed the effect of statins in patients with HIV and metabolic syndrome, as they are usually associated with systemic inflammation and higher cardiovascular risk.
Impact of BMI on the Outcomes of Intensive LDL-C Lowering Therapy
Patients receiving intensive low-density lipoprotein-cholesterol-lowering therapy may have better clinical outcomes when their body mass index is normal vs high.
Gestational Diabetes Associated With Increased Risk for Future Dyslipidemia
A history of gestational diabetes is associated with increased risk for dyslipidemia.
Tool Developed to Assess Long-Term CVD Risk, Benefit of Lipid-Lowering Intervention
The blood levels of non-high density lipoprotein cholesterol were found to have a strong association with the long-term risk for a cardiovascular disease event.
Whey Protein Supplementation May Reduce Components of Metabolic Syndrome
Pooled data from a systematic review and meta-analysis indicated that supplementation with whey protein reduced individual components of metabolic syndrome.
FOURIER Trial Reviewed: Are the Expensive PCSK9 Inhibitors Right for Your Patients?
At the current price of the drug, and lacking sufficient mortality data, treating patients for longer periods of time with expensive PCSK9 inhibitors is likely to result only in large profits for the company.
-
Loading...
-
Loading...
